News

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.

Designing a transitions of care stewardship program and engaging all stakeholders can help cut down on unnecessary antibiotic prescriptions.

Can clinicians rely on dosing strategy to avoid acute kidney injury for patients receiving vancomycin with a β-lactam like piperacillin-tazobactam?

Investigators sought information on how the infection is treated in outpatient clinics

Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.

A MAD-ID 2022 poster sought to better understand the current antibiotic prescribing patterns at adult primary care clinics affiliated with Maimonides Medical Center in New York.

In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing PrEP with their patients.

A study looked at the utilization of the technology with this antibiotic class in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000 patients with C diff.

AdventHealth Orlando studied a small number of these fungal isolates to examine treatment resistance patterns.

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.

In hospitalized COVID-19 patients, remdesivir stewardship reduced hospital length of stay and therapy duration.

Colleen R. Kelly, MD, FACG, speaks at MAD-ID 2022 on alternatives to antibiotics for C diff infection, including the use of probiotics and fecal microbiota transplantation.

The CDC’s COVID-19 booster dose recommendation for children 5 and older comes a few days after the FDA’s authorization

“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.

Among community-acquired pneumonia (CAP) outpatients, 49% were prescribed unnecessary antibiotics.

Leveraging antimicrobial stewardship programs was crucial to ensure COVID-19 hospital inpatients received monoclonal antibody therapy quickly and safely.

To reduce the risk of antimicrobial resistance, rapid laboratory diagnostics are needed to identify the pathogens in hospital patients with COVID-19 and sepsis.

A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.

The FDA lifted a clinical hold on investigational lenacapavir for HIV treatment and pre-exposure prophylaxis. All clinical studies evaluating injectable lenacapavir can now resume.

Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.

A new study in the United Kingdom provided evidence in support of a fourth dose of COVID-19 vaccines, showing a strong boost in immunity.

A third, “booster,” dose of the Pfizer-BioNTech COVID-19 vaccine is now FDA-approved for children 5-11 years old.

As we recently surpassed the 2-year mark of the pandemic, the May issue reflects on lessons learned thus far.

This is the first test authorized for all 3 viruses and is over the counter.

Though it failed to meet its primary study endpoints, post hoc analysis of SNG001 showed the inhalable reduced the risk of severe COVID-19 disease and death in high-risk patients.

Stage 2/3 trials are underway to test the efficacy of J08, a potent monoclonal antibody, to prevent and treat current and future COVID-19 variants.

Tend, a startup company, has developed its Gut Microbiome Collect and Prep (CAP) to enable a standardized method for stool (microbiome) encapsulation for the procedure.